578 related articles for article (PubMed ID: 25982279)
1. Targeting JAK kinase in solid tumors: emerging opportunities and challenges.
Buchert M; Burns CJ; Ernst M
Oncogene; 2016 Feb; 35(8):939-51. PubMed ID: 25982279
[TBL] [Abstract][Full Text] [Related]
2. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Lai SY; Johnson FM
Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
[TBL] [Abstract][Full Text] [Related]
3. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.
Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ
Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236
[TBL] [Abstract][Full Text] [Related]
4. The JAK/STAT3 axis: A comprehensive drug target for solid malignancies.
Huynh J; Etemadi N; Hollande F; Ernst M; Buchert M
Semin Cancer Biol; 2017 Aug; 45():13-22. PubMed ID: 28647610
[TBL] [Abstract][Full Text] [Related]
5. The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review).
Wang SW; Sun YM
Int J Oncol; 2014 Apr; 44(4):1032-40. PubMed ID: 24430672
[TBL] [Abstract][Full Text] [Related]
6. Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.
Murone M; Vaslin Chessex A; Attinger A; Ramachandra R; Shetty SJ; Daginakatte G; Sengupta S; Marappan S; Dhodheri S; Rigotti S; Bachhav Y; Brienza S; Traxler P; Lang M; Aguet M; Zoete V; Michielin O; Nicholas C; Johnson FM; Ramachandra M; McAllister A
Mol Cancer Ther; 2016 Oct; 15(10):2334-2343. PubMed ID: 27439479
[TBL] [Abstract][Full Text] [Related]
7. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
[TBL] [Abstract][Full Text] [Related]
8. The many faces of Janus kinase.
Seavey MM; Dobrzanski P
Biochem Pharmacol; 2012 May; 83(9):1136-45. PubMed ID: 22209716
[TBL] [Abstract][Full Text] [Related]
9. Targeting the IL-6/JAK/STAT3 signalling axis in cancer.
Johnson DE; O'Keefe RA; Grandis JR
Nat Rev Clin Oncol; 2018 Apr; 15(4):234-248. PubMed ID: 29405201
[TBL] [Abstract][Full Text] [Related]
10. JAK/STAT pathway plays a critical role in the proinflammatory gene expression and apoptosis of RAW264.7 cells induced by trichothecenes as DON and T-2 toxin.
Wang X; Liu Q; Ihsan A; Huang L; Dai M; Hao H; Cheng G; Liu Z; Wang Y; Yuan Z
Toxicol Sci; 2012 Jun; 127(2):412-24. PubMed ID: 22454431
[TBL] [Abstract][Full Text] [Related]
11. Zelnorm, an agonist of 5-Hydroxytryptamine 4-receptor, acts as a potential antitumor drug by targeting JAK/STAT3 signaling.
Zhang L; Song Q; Zhang X; Li L; Xu X; Xu X; Li X; Wang Z; Lin Y; Li X; Li M; Su F; Wang X; Qiu P; Guan H; Tang Y; Xu W; Yang J; Zhao C
Invest New Drugs; 2020 Apr; 38(2):311-320. PubMed ID: 31087223
[TBL] [Abstract][Full Text] [Related]
12. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
[TBL] [Abstract][Full Text] [Related]
13. Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells.
Chen X; Du Y; Nan J; Zhang X; Qin X; Wang Y; Hou J; Wang Q; Yang J
PLoS One; 2013; 8(5):e63697. PubMed ID: 23704931
[TBL] [Abstract][Full Text] [Related]
14. Selective JAK/STAT3 signalling regulates transcription of colony stimulating factor-2 and -3 in Concanavalin-A-activated mesenchymal stromal cells.
Zgheib A; Pelletier-Bonnier É; Levros LC; Annabi B
Cytokine; 2013 Aug; 63(2):187-93. PubMed ID: 23688618
[TBL] [Abstract][Full Text] [Related]
15. JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.
Springuel L; Renauld JC; Knoops L
Haematologica; 2015 Oct; 100(10):1240-53. PubMed ID: 26432382
[TBL] [Abstract][Full Text] [Related]
16. JAK kinases overexpression promotes in vitro cell transformation.
Knoops L; Hornakova T; Royer Y; Constantinescu SN; Renauld JC
Oncogene; 2008 Mar; 27(11):1511-9. PubMed ID: 17873904
[TBL] [Abstract][Full Text] [Related]
17. 17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells.
Wang Y; Ma X; Yan S; Shen S; Zhu H; Gu Y; Wang H; Qin G; Yu Q
Cancer Res; 2009 Sep; 69(18):7302-10. PubMed ID: 19706767
[TBL] [Abstract][Full Text] [Related]
18. Activation of the JAK-STAT3 pathway is associated with the growth of colorectal carcinoma cells.
Wei X; Wang G; Li W; Hu X; Huang Q; Xu K; Lou W; Wu J; Liang C; Lou Q; Qian C; Liu L
Oncol Rep; 2014 Jan; 31(1):335-41. PubMed ID: 24253664
[TBL] [Abstract][Full Text] [Related]
19. Cell density dependent increase of constitutive signal transducers and activators of transcription 3 activity in melanoma cells is mediated by Janus kinases.
Kreis S; Munz GA; Haan S; Heinrich PC; Behrmann I
Mol Cancer Res; 2007 Dec; 5(12):1331-41. PubMed ID: 18171991
[TBL] [Abstract][Full Text] [Related]
20. Anti-angiogenic activity of thienopyridine derivative LCB03-0110 by targeting VEGFR-2 and JAK/STAT3 Signalling.
Kim BH; Lee Y; Yoo H; Cui M; Lee S; Kim SY; Cho JU; Lee H; Yang BS; Kwon YG; Choi S; Kim TY
Exp Dermatol; 2015 Jul; 24(7):503-9. PubMed ID: 25808463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
